Jankowski Wojciech Michał, Fichna Jakub, Tarasiuk-Zawadzka Aleksandra
Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Mazowiecka 5, 92-215, Lodz, Poland.
Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Mazowiecka 5, 92-215, Lodz, Poland.
Microb Pathog. 2025 Feb;199:107214. doi: 10.1016/j.micpath.2024.107214. Epub 2024 Dec 9.
Acute pancreatitis (AP) represents one of the most common gastrointestinal (GI) diseases; it can manifest in varying degrees of severity, sometimes leading to a life-threatening condition for the patient. Pancreatic ductal adenocarcinoma (PDAC), due to its high malignancy and uncertain prognosis, is widely regarded as one of the most fatal diseases. The increasing prevalence of AP and PDAC represents a major burden on public health and the healthcare system worldwide. The aim of this systematic review was to discuss the current state of knowledge regarding the relationship between the gut microbiota and the incidence, prognosis, diagnosis and treatment of AP and PDAC. To identify studies that analyzed the relationship between the gut microbiota and the occurrence/development of pancreatic diseases or PDAC, the online databases PubMed, Scopus and Google Scholar were searched between November 2023 and January 2024. Finally, 14 publications met the inclusion criteria (1. were conducted exclusively in humans and/or animals; 2. original, published in English in peer-reviewed journals after 2019; 3. described the relationship between gut microbiota and the occurrence of AP or PDAC). The collected studies indicated significant changes in the gut microbiota of patients with AP and PDAC. Moreover, they highlighted the presence of a relationship between the gut microbiota and the occurrence, course, treatment efficiency and prognosis of the disease in question. Further research is needed to understand precisely the relationship between the gut microbiota and the occurrence of pancreatic diseases and whether it may be a starting point for the development of modern forms of therapy based on the use of prebiotics and/or diet to restore the normal composition of the intestinal bacteria.
急性胰腺炎（AP）是最常见的胃肠道疾病之一；其严重程度各异，有时会导致患者生命垂危。胰腺导管腺癌（PDAC）因其高恶性和预后不确定，被广泛认为是最致命的疾病之一。AP和PDAC患病率的上升给全球公共卫生和医疗系统带来了重大负担。本系统综述的目的是探讨关于肠道微生物群与AP和PDAC的发病率、预后、诊断及治疗之间关系的现有知识状况。为了确定分析肠道微生物群与胰腺疾病或PDAC发生/发展之间关系的研究，于2023年11月至2024年1月期间检索了在线数据库PubMed、Scopus和谷歌学术。最终，14篇出版物符合纳入标准（1. 仅在人类和/或动物中进行；2. 原创，2019年后在同行评审期刊上以英文发表；3. 描述了肠道微生物群与AP或PDAC发生之间的关系）。收集到的研究表明，AP和PDAC患者的肠道微生物群有显著变化。此外，这些研究突出了肠道微生物群与所讨论疾病的发生、病程、治疗效果和预后之间存在关联。需要进一步研究以准确了解肠道微生物群与胰腺疾病发生之间的关系，以及它是否可能成为基于使用益生元和/或饮食来恢复肠道细菌正常组成的现代治疗形式发展的起点。
